VISTA-1
Brief Summary
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
Official Title
A Randomized, Double‑Blind, Placebo‑Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects with Advanced, Metastatic, and Progressive Colorectal Cancer (NCT06824064)
Conditions
Metastatic Colorectal Cancer,Advanced Colorectal Cancer
Pfizer C6461003
Brief Summary
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before.
Official Title
An Interventional, Phase 3, Double‑Blind, Randomized Study to Evaluate the Efficacy and Safety of PF‑08634404 in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Treatment‑Naïve Participants With Metastatic Colorectal Cancer (NCT07222800)
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
